Abstract
This work demonstrated the constitutive expression of peroxisome proliferator-activated receptor (PPAR)-gamma and PPAR-alpha in rat synovial fibroblasts at both mRNA and protein levels. A decrease in PPAR-gamma expression induced by 10 microg/ml lipopolysaccharide (LPS) was observed, whereas PPAR-alpha mRNA expression was not modified. 15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) dose-dependently decreased LPS-induced cyclooxygenase (COX)-2 (-80%) and inducible nitric oxide synthase (iNOS) mRNA expression (-80%), whereas troglitazone (10 microM) only inhibited iNOS mRNA expression (-50%). 15d-PGJ(2) decreased LPS-induced interleukin (IL)-1 beta (-25%) and tumor necrosis factor (TNF)-alpha (-40%) expression. Interestingly, troglitazone strongly decreased TNF-alpha expression (-50%) but had no significant effect on IL-1 beta expression. 15d-PGJ(2) was able to inhibit DNA-binding activity of both nuclear factor (NF)-kappa B and AP-1. Troglitazone had no effect on NF-kappa B activation and was shown to increase LPS-induced AP-1 activation. 15d-PGJ(2) and troglitazone modulated the expression of LPS-induced iNOS, COX-2, and proinflammatory cytokines differently. Indeed, troglitazone seems to specifically target TNF-alpha and iNOS pathways. These results offer new insights in regard to the anti-inflammatory potential of the PPAR-gamma ligands and underline different mechanisms of action of 15d-PGJ(2) and troglitazone in synovial fibroblasts.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Cells, Cultured
-
Chromans / pharmacology
-
Cyclooxygenase 2
-
Fibroblasts / cytology
-
Fibroblasts / drug effects
-
Fibroblasts / metabolism*
-
Gene Expression / drug effects
-
Gene Expression / physiology
-
Interleukin-1 / genetics
-
Isoenzymes / genetics
-
Ligands
-
Lipopolysaccharides / pharmacology*
-
Male
-
NF-kappa B / antagonists & inhibitors
-
Nitric Oxide Synthase / genetics
-
Nitric Oxide Synthase Type II
-
Prostaglandin D2 / analogs & derivatives*
-
Prostaglandin D2 / pharmacology
-
Prostaglandin-Endoperoxide Synthases / genetics
-
RNA, Messenger / analysis
-
Rats
-
Rats, Wistar
-
Receptors, Cytoplasmic and Nuclear / genetics
-
Receptors, Cytoplasmic and Nuclear / metabolism*
-
Synovial Membrane / cytology*
-
Synovial Membrane / immunology
-
Thiazoles / pharmacology
-
Thiazolidinediones*
-
Transcription Factor AP-1 / antagonists & inhibitors
-
Transcription Factors / genetics
-
Transcription Factors / metabolism*
-
Troglitazone
-
Tumor Necrosis Factor-alpha / genetics
Substances
-
Antineoplastic Agents
-
Chromans
-
Interleukin-1
-
Isoenzymes
-
Ligands
-
Lipopolysaccharides
-
NF-kappa B
-
RNA, Messenger
-
Receptors, Cytoplasmic and Nuclear
-
Thiazoles
-
Thiazolidinediones
-
Transcription Factor AP-1
-
Transcription Factors
-
Tumor Necrosis Factor-alpha
-
9-deoxy-delta-9-prostaglandin D2
-
Nitric Oxide Synthase
-
Nitric Oxide Synthase Type II
-
Nos2 protein, rat
-
Cyclooxygenase 2
-
Prostaglandin-Endoperoxide Synthases
-
Troglitazone
-
Prostaglandin D2